FI3858375T3 - Hyytymishäiriön hoito antamalla rekombinanttia von Willebrand -tekijää - Google Patents

Hyytymishäiriön hoito antamalla rekombinanttia von Willebrand -tekijää Download PDF

Info

Publication number
FI3858375T3
FI3858375T3 FIEP20216368.9T FI20216368T FI3858375T3 FI 3858375 T3 FI3858375 T3 FI 3858375T3 FI 20216368 T FI20216368 T FI 20216368T FI 3858375 T3 FI3858375 T3 FI 3858375T3
Authority
FI
Finland
Prior art keywords
rvwf
use according
von willebrand
treatment
willebrand factor
Prior art date
Application number
FIEP20216368.9T
Other languages
English (en)
Finnish (fi)
Inventor
Friedrich Scheiflinger
Peter Turecek
Bruce Ewenstein
Wing Yen Wong
Tobias M Suiter
Original Assignee
Takeda Pharmaceuticals Co
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Takeda Pharmaceuticals Co filed Critical Takeda Pharmaceuticals Co
Application granted granted Critical
Publication of FI3858375T3 publication Critical patent/FI3858375T3/fi

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/36—Blood coagulation or fibrinolysis factors
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/36—Blood coagulation or fibrinolysis factors
    • A61K38/37—Factors VIII
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/08—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing oxygen, e.g. ethers, acetals, ketones, quinones, aldehydes, peroxides
    • A61K47/10—Alcohols; Phenols; Salts thereof, e.g. glycerol; Polyethylene glycols [PEG]; Poloxamers; PEG/POE alkyl ethers
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
    • A61P7/02—Antithrombotic agents; Anticoagulants; Platelet aggregation inhibitors
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
    • A61P7/04—Antihaemorrhagics; Procoagulants; Haemostatic agents; Antifibrinolytic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K2300/00—Mixtures or combinations of active ingredients, wherein at least one active ingredient is fully defined in groups A61K31/00 - A61K41/00

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Hematology (AREA)
  • Epidemiology (AREA)
  • Zoology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Immunology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Organic Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Diabetes (AREA)
  • Oil, Petroleum & Natural Gas (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Medicinal Preparation (AREA)
  • Preparation Of Compounds By Using Micro-Organisms (AREA)
  • Peptides Or Proteins (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Heterocyclic Compounds Containing Sulfur Atoms (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
FIEP20216368.9T 2011-06-10 2012-06-11 Hyytymishäiriön hoito antamalla rekombinanttia von Willebrand -tekijää FI3858375T3 (fi)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US201161495884P 2011-06-10 2011-06-10
US201161511901P 2011-07-26 2011-07-26
US201161523790P 2011-08-15 2011-08-15

Publications (1)

Publication Number Publication Date
FI3858375T3 true FI3858375T3 (fi) 2024-04-17

Family

ID=46321496

Family Applications (1)

Application Number Title Priority Date Filing Date
FIEP20216368.9T FI3858375T3 (fi) 2011-06-10 2012-06-11 Hyytymishäiriön hoito antamalla rekombinanttia von Willebrand -tekijää

Country Status (23)

Country Link
US (3) US9272021B2 (enExample)
EP (3) EP3412305B1 (enExample)
JP (3) JP6347468B2 (enExample)
KR (3) KR102319868B1 (enExample)
CN (3) CN103732244A (enExample)
AR (1) AR086904A1 (enExample)
AU (5) AU2012267458A1 (enExample)
CA (1) CA2838845C (enExample)
DK (3) DK3858375T3 (enExample)
ES (3) ES2976169T3 (enExample)
FI (1) FI3858375T3 (enExample)
HK (1) HK1257436A1 (enExample)
HR (1) HRP20180962T1 (enExample)
HU (1) HUE039317T2 (enExample)
LT (1) LT2717905T (enExample)
MX (2) MX350582B (enExample)
PL (3) PL3858375T3 (enExample)
PT (3) PT2717905T (enExample)
RU (2) RU2628537C2 (enExample)
SG (2) SG10201604684WA (enExample)
SI (1) SI2717905T1 (enExample)
TR (1) TR201808823T4 (enExample)
WO (1) WO2012171031A1 (enExample)

Families Citing this family (16)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN103732244A (zh) * 2011-06-10 2014-04-16 巴克斯特国际公司 通过施用重组vwf治疗凝血疾病
CN102776260B (zh) * 2012-07-26 2015-04-29 上海泰龙生物医药科技有限公司 一种高效表达重组人凝血八因子的方法
EP2796145B1 (en) * 2013-04-22 2017-11-01 CSL Ltd. A covalent complex of von willebrand factor and faktor viii linked by a disulphide bridge
NL2013007B1 (en) 2014-06-16 2016-07-05 Ablynx Nv Methods of treating TTP with immunoglobulin single variable domains and uses thereof.
FR3034669B1 (fr) 2015-04-07 2020-02-14 Laboratoire Francais Du Fractionnement Et Des Biotechnologies Nouvelle utilisation du facteur von willebrand
CN109804432B (zh) 2016-04-15 2023-07-14 武田药品工业株式会社 提供药代动力学药物给药方案的方法和设备
US10896749B2 (en) 2017-01-27 2021-01-19 Shire Human Genetic Therapies, Inc. Drug monitoring tool
FI3648788T5 (fi) 2017-07-07 2024-09-09 Takeda Pharmaceuticals Co Maha-suolikanavan verenvuodon hoito vaikeaa von willebrandin tautia sairastavilla potilailla antamalla rekombinanttia vwf:ää
JP7326246B2 (ja) 2017-07-07 2023-08-15 武田薬品工業株式会社 待機手術を受ける、重度のフォンヴィレブランド病を患う患者の、組換えｖｗｆの投与による治療法
MX2020008294A (es) 2018-02-06 2020-11-18 Ablynx Nv Metodos de tratamiento de episodio inicial de ttp con dominios variables simples de inmunoglobulina.
CA3094644A1 (en) * 2018-03-21 2019-09-26 Baxalta Incorporated Separation of vwf and vwf propeptide by chromatographic methods
EA202192140A1 (ru) * 2019-02-01 2021-12-15 Такеда Фармасьютикал Компани Лимитед СПОСОБЫ ПРОФИЛАКТИЧЕСКОГО ЛЕЧЕНИЯ РЕКОМБИНАНТНЫМ ФВ (рФВ)
JP2022547556A (ja) * 2019-09-11 2022-11-14 武田薬品工業株式会社 フォン・ヴィレブランド因子と補体ｃ１ｑの複合体に関連する治療法
CA3169996A1 (en) 2020-02-04 2021-08-12 Takeda Pharmaceutical Company Limited Treatment of menorrhagia in patients with severe von willebrand disease by administration of recombinant vwf
EP4251272A4 (en) * 2020-11-24 2024-10-09 Band Therapeutics, LLC COMPOSITIONS AND METHODS FOR THE TREATMENT OF BLEEDING DISORDERS
WO2024124136A1 (en) * 2022-12-09 2024-06-13 Vega Therapeutics, Inc. Von willebrand disease animal models

Family Cites Families (32)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4179337A (en) 1973-07-20 1979-12-18 Davis Frank F Non-immunogenic polypeptides
JPS6023084B2 (ja) 1979-07-11 1985-06-05 味の素株式会社 代用血液
US4640835A (en) 1981-10-30 1987-02-03 Nippon Chemiphar Company, Ltd. Plasminogen activator derivatives
US4496689A (en) 1983-12-27 1985-01-29 Miles Laboratories, Inc. Covalently attached complex of alpha-1-proteinase inhibitor with a water soluble polymer
US4638028A (en) 1985-04-08 1987-01-20 Goodyear Tire & Rubber Company Rubber polymerases and methods for their production and use
WO1986006096A1 (en) 1985-04-11 1986-10-23 The Children's Medical Center Corporation Von willebrand factor
EP0206448B1 (en) 1985-06-19 1990-11-14 Ajinomoto Co., Inc. Hemoglobin combined with a poly(alkylene oxide)
US4791192A (en) 1986-06-26 1988-12-13 Takeda Chemical Industries, Ltd. Chemically modified protein with polyethyleneglycol
SE504074C2 (sv) * 1993-07-05 1996-11-04 Pharmacia Ab Proteinberedning för subkutan, intramuskulär eller intradermal administrering
DE4435485C1 (de) * 1994-10-04 1996-03-21 Immuno Ag Verfahren zur Gewinnung von hochreinem von Willebrand-Faktor
AT403764B (de) * 1996-03-15 1998-05-25 Immuno Ag Stabiler faktor viii/vwf-komplex
AT406373B (de) * 1997-02-27 2000-04-25 Immuno Ag Verfahren zur reinigung von faktor viii/vwf-komplex mittels kationenaustauscherchromatographie
AT405403B (de) * 1997-02-27 1999-08-25 Immuno Ag Reinigung von von willebrand-faktor durch kationenaustauscherchromatographie
US6531577B1 (en) 1997-12-15 2003-03-11 Hemasure Denmark A/S von Willebrand factor (vWF)-containing preparation, process for preparing vWF-containing preparations, and use of such preparations
US6864403B1 (en) 1998-10-15 2005-03-08 E. I. Du Pont De Nemours And Company Plant protein disulfide isomerases
US20040014657A1 (en) * 2001-11-05 2004-01-22 Jan Ohrstrom Use of blood coagulation factor XIII for treating haemophilia A
WO2005012354A1 (en) * 2003-07-31 2005-02-10 Zlb Behring Gmbh Method for extending the half-life of fviii
EP1593388A1 (en) * 2004-05-05 2005-11-09 ZLB Behring GmbH Therapeutic plasma protein-concentrates containing von willebrand factor as high molecular weight multimers
US20060094104A1 (en) 2004-10-29 2006-05-04 Leopold Grillberger Animal protein-free media for cultivation of cells
AU2005322067B8 (en) * 2004-12-27 2012-07-26 Takeda Pharmaceutical Company Limited Polymer-von Willebrand factor-conjugates
ES2474573T3 (es) 2006-01-04 2014-07-09 Baxter International Inc Medio de cultivo celular sin oligop�ptidos
PL2167117T3 (pl) * 2007-06-13 2013-01-31 Csl Behring Gmbh Zastosowanie stabilizowanego VWP preparatu FVIII do podawania pozanaczyniowego w terapii i profilaktyce zaburzeń krzepliwości krwi
AU2008323768A1 (en) 2007-11-09 2009-05-14 Baxter Healthcare S.A. Modified recombinant Factor VIII and von Willebrand Factor and methods of use
JP2009127455A (ja) 2007-11-20 2009-06-11 Bando Kiko Co Ltd 往復動エンジン
EP2244814B1 (en) * 2007-12-28 2021-06-02 Takeda Pharmaceutical Company Limited Recombinant vwf formulations
ES2298096B1 (es) * 2008-01-08 2009-01-01 Grifols, S.A. Procedimiento para la obtencion de un concentrado de factor von willebrand o del complejo de factor viii/factor von willebrand y utilizacionde los mismos.
EP2865760B1 (en) 2008-06-24 2017-10-11 CSL Behring GmbH Factor viii, von willebrand factor or complexes thereof with prolonged in vivo half-life
EP2349314B1 (en) * 2008-10-21 2013-02-27 Baxter International Inc. Lyophilized recombinant vwf formulations
US20110072524A1 (en) * 2009-08-04 2011-03-24 Baxter International Inc. Transgenic Mouse Lacking Endogenous FVIII and VWF - A Model of Hemophilia A
EA202090067A3 (ru) 2010-07-08 2020-07-31 Баксалта Инкорпорейтид Способ получения рекомбинантного adamts13 в культуре клеток
US20120006800A1 (en) 2010-07-09 2012-01-12 Illinois Tool Works Inc. Weld bead feature communication systems and devices
CN103732244A (zh) * 2011-06-10 2014-04-16 巴克斯特国际公司 通过施用重组vwf治疗凝血疾病

Also Published As

Publication number Publication date
WO2012171031A1 (en) 2012-12-13
JP6347468B2 (ja) 2018-06-27
RU2019103386A3 (enExample) 2022-01-24
KR20200091476A (ko) 2020-07-30
CN107412743B (zh) 2021-07-02
PT2717905T (pt) 2018-07-02
HRP20180962T1 (hr) 2018-10-19
EP3858375B1 (en) 2024-03-20
PL2717905T3 (pl) 2018-10-31
EP3412305B1 (en) 2021-01-06
TR201808823T4 (tr) 2018-07-23
DK2717905T3 (en) 2018-07-02
EP3858375A1 (en) 2021-08-04
DK3858375T3 (da) 2024-04-15
PT3858375T (pt) 2024-04-18
JP2017019788A (ja) 2017-01-26
ES2860450T3 (es) 2021-10-05
NZ618790A (en) 2015-07-31
AU2017206235A1 (en) 2017-08-03
CN103732244A (zh) 2014-04-16
MX2013014543A (es) 2014-06-11
CN108210889A (zh) 2018-06-29
ES2682249T3 (es) 2018-09-19
CA2838845C (en) 2019-08-06
AU2017206235B2 (en) 2019-10-17
US20120316116A1 (en) 2012-12-13
AU2012267458A1 (en) 2014-01-09
HK1257436A1 (zh) 2019-10-18
CN107412743A (zh) 2017-12-01
HUE039317T2 (hu) 2018-12-28
SG10202002591QA (en) 2020-05-28
EP2717905A1 (en) 2014-04-16
RU2628537C2 (ru) 2017-08-18
LT2717905T (lt) 2018-10-10
RU2017102679A3 (enExample) 2018-12-19
ES2976169T3 (es) 2024-07-24
RU2680402C2 (ru) 2019-02-21
SI2717905T1 (sl) 2018-09-28
JP6527114B2 (ja) 2019-06-05
AR086904A1 (es) 2014-01-29
KR102319868B1 (ko) 2021-11-01
EP2717905B1 (en) 2018-05-23
RU2017102679A (ru) 2018-12-19
SG10201604684WA (en) 2016-07-28
JP2019048892A (ja) 2019-03-28
MX2020000083A (es) 2020-08-06
KR20190041032A (ko) 2019-04-19
EP3412305A1 (en) 2018-12-12
US20160184403A1 (en) 2016-06-30
AU2020200026A1 (en) 2020-01-30
AU2022201518B2 (en) 2025-07-03
PL3412305T3 (pl) 2021-05-31
DK3412305T3 (da) 2021-03-01
AU2022201518A1 (en) 2022-03-24
JP2014516088A (ja) 2014-07-07
AU2016202299A1 (en) 2016-05-05
BR112013031795A2 (pt) 2016-12-20
MX350582B (es) 2017-09-11
RU2014100107A (ru) 2015-07-20
US20250387455A1 (en) 2025-12-25
PT3412305T (pt) 2021-01-29
CA2838845A1 (en) 2012-12-13
AU2016202299B2 (en) 2017-07-20
KR101969515B1 (ko) 2019-04-16
PL3858375T3 (pl) 2024-05-20
RU2019103386A (ru) 2020-08-07
US9272021B2 (en) 2016-03-01
KR20140039285A (ko) 2014-04-01

Similar Documents

Publication Publication Date Title
Napoli et al. Endothelial progenitor cells as therapeutic agents in the microcirculation: an update
AU2018256635A1 (en) Methods for treating anemia
RU2017102679A (ru) Лечение нарушений свертываемости крови путем введения рекомбинантного фв
EP3418386A3 (en) Compositions and methods for inhibiting gene expression of hepatitis b virus
MX2014009480A (es) Metodo compartimentado de administracion de acidos nucleicos y composiciones y usos del mismo.
NZ602471A (en) Antagonists of activin-actriia and uses for increasing red blood cell levels
MX2014014840A (es) Peptido - mimeticos de la horquilla beta.
JP2009137992A5 (enExample)
MA37400A1 (fr) Composés hétérocyclyle en tant qu'inhibiteurs de mek
PH12014501937A1 (en) Pharmaceutical composition containing an antivirally active dihydroquinazoline derivative
WO2013120012A3 (en) Cdim binding proteins and uses thereof
EP2853543A8 (en) Anti-blys antibody
JP2014516088A5 (enExample)
JP2014501492A5 (enExample)
AR088294A1 (es) Determinacion de polimorfismos de un nucleotido simple utiles para predecir la respuesta clinica al acetato de glatiramero
PH12014502366A1 (en) Injectable formulation
MX343205B (es) Peptidomiméticos de horquilla beta como antagonistas de cxc4.
PH12014501579A1 (en) Combination of beta-hydroxy-beta-methylbutyrate, arginine and glutamine for use in treating diabetic ulcers
WO2012177660A3 (en) Leukotoxin e/d as a new anti-inflammatory agent and microbicide
MX349364B (es) Variante de alfa-1 antitripsina novedosa, método de preparación de la misma, y uso de la misma.
HK1216007A1 (zh) 人体生长激素和白蛋白的融合、制剂及其用途
BR112015022730A2 (pt) formulações de rfviii, método para conjugação covalente de rfviii com um polímero biocompatível e uso de rfviii no preparo de formulação de rfviii para tratamento de hemofilia a
AR124709A2 (es) FACTOR DE VON WILLEBRAND RECOMBINANTE (rVWF) ÚTIL EN LA ENFERMEDAD DE VON WILLEBRAND O HEMOFILIA A
WO2016195338A3 (ko) 액정 나노 입자, 이의 제조방법 및 친유성 약물이 봉입된 액정 나노입자를 함유하는 약물 전달 시스템
DE602006003848D1 (de) Formulierung zur verzögerten Freisetzung von Valproinsäure und deren Derivate